Health Condition 1: null- Non Alcoholic Fatty Liver Disease
Conditions
Interventions
Intervention1: Metformin,Metadoxine: 500 mg BD for 3 months
Intervention2: Not Applicable: Not Applicable
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Osmania General Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Type II Diabetes Mellitus and Metabolic Syndrome a. Fasting Blood Sugar >120 mg/dL b. Metabolic Syndrome diagnosed as per NCEP- ATP III criteria. 2. Patients with age >=18 years. 3. Patient with stable dose of diabetic medication for last three months. 4. Alcohol intake of
Exclusion criteria
Exclusion criteria: 1. Patient taking Thiazolidinedioneâ??s 2. Patients with cirrhosis. 3. Patients with NYHA class III-IV. 4. Patients having neurological disease. 5. Patient with uncontrolled blood pressure( 3 antihypertensive medication) 6. Patients on Drugs known to induce fatty liver such as methotrexate, estrogens, tamoxifen and amiodarone. 7. Unable to be followed for the duration of the clinical trial 8. Inability to obtain informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a)To assess the prevalence and incidence of Non-Alcoholic Fatly Liver Disease (NAFLD) in patients with Diabetes and Metabolic Syndrome. b) Anthropometric measures.Timepoint: From enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT alanine aminotransferase at the end of three months of treatment.Timepoint: From enrollment to 3 months;AST aspartate aminotransferase at the end of three months of treatment.Timepoint: from enrollment to 3 months | — |
Countries
India
Contacts
Public ContactDr Rakesh Kumar Sahay
Osmania Medical College and Hospital
Outcome results
None listed